Alan Sheyman
Retina Specialist · New York, NYNPI 1659663268
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,205 of the $3,763 with a category attached, or 85.2%. 11 manufacturers reported payments, led by Eyepoint US, Inc. at 39.9% of the total. Reporting peaked in 2024 at $1,751 and has fallen 90.7% since, to $163 in 2025.
Across 18 payments — averaging $209.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eyepoint US, Inc.$2K
- AbbVie$1K
- Lupin Inc.$375
- Bausch & Lomb Americas Inc.$239
- Alcon$95
- Bausch & Lomb, A Division Of Bausch Health US, LLC$50
- plus $102 from 5 others
What the payments were for
- Consulting fees$3,20585%
- Food & beverage$55815%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eyepoint US, Inc. | 1 | $1,500 |
| AbbVie(2 entities) | 4 | $1,402 |
| Lupin Inc. | 1 | $375 |
| Bausch & Lomb Americas Inc. | 2 | $239 |
| Alcon | 2 | $95 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $50 |
| Alimera Sciences, Inc. | 1 | $25 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $23 |
| Mallinckrodt Hospital Products Inc. | 1 | $23 |
| Genentech USA, Inc. | 1 | $17 |
| Astellas Pharma US Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYP-1901$1,500
- OZURDEX$1,330
- enVista MX60 IOL$150
How this compares
$3,763 in reported general payments places this provider in the 60th percentile of 99 retina specialist providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 107 | $3,717 |
| Ketorolac Tromethamine | 113 | $2,532 |
| Brimonidine Tartrate | 65 | $2,230 |
| Travoprost | 19 | $2,041 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 60 | $1,057 |
| Latanoprost | 66 | $475 |
| Timolol Maleate | 31 | $252 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in New York
- Szilard KissNew York$195K
- Donald D'amicoNew York$109K
- Gareth LemaNew York$11K
- Megan Ridley LaneNew York$11K
- Carl WilkinsNew York$9K
- Gennady LandaNew York$7K
- Joseph TsengNew York$6K
- Ben CohenNew York$5K
- Steven AgemyNew York$3K
- Louis AngiolettiNew York$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.